Abstract: The present invention relates to the field of medicine, in particular of research and diagnosis. It relates more particularly to a novel tool for detecting antibodies in a biological sample originating from a mammal. This tool, which is in the form of a protein chip, can be used in screening for new targets of interest involved in the occurrence of an autoimmune disease, in particular of a disease affecting the nervous system of a mammal, and also in the diagnosis or the monitoring of the progression of such an autoimmune disease. The invention also relates to a method for producing such a tool and also to kits comprising it and enabling its use.

Abstract: The present invention relates to a method for preparing a vaccine antigen, which includes a step of fragmenting a biological membrane associated with said vaccine antigen by treating said biological membrane with at least one calixarene of formula (II): wherein: X is a —(CH2)-CO2Y group and Y is an alkaline metal or one of the pharmaceutically acceptable salts thereof, wherein said resulting vaccine antigen also includes a fragment of the biological membrane associated with said antigen. The present invention also relates to a vaccine that can be produced by implementing the method, including a calixarene of formula (II) in carrier format, with a quantity of 0.1 to 1,000 ?g in the total weight of the vaccine. The present invention further relates to the use of a calixarene as defined above for the preparation of a vaccine or a vaccine antigen, and to the vaccine for use as a drug in the treatment or prevention of an infectious disease.

Abstract: The present invention relates to a process for determining in vitro the immune status of an individual according to which: (a) a blood sample from the individual is provided, (b) at least two reagents specific to at least two products of expression of at least two target genes are provided; (c) the expression of said at least two target genes is determined, and (d) the expression of said at least two target genes respectively is compared with a reference expression, with a change in the expression of said at least two target genes relative to their reference expression indicating that the individual's immune status has changed, and a correlation between the expression of said at least two target genes with their reference expression indicating that the individual's immune status is normal; as well as a kit for determining said immune status of the individual.

Abstract: A computer-based method is herein disclosed, allowing to differentiate automatically between two tissues of interest: an extrinsic and an intrinsic tissue, from a plurality of images, obtaining a quantitative assessment of each of said tissues without requiring the intervention of an expert. Said method involves the definition of a differentiation region in images obtained from a medical imaging acquisition device using a parametric contour, after which differentiation and quantification are carried out based on the photometric characteristics of the different tissues observed in images, evaluating the local neighborhood of each voxel belonging to the differentiation region previously defined in the plurality of images. The disclosed method increases to a great extent precision in differentiation and quantification of tissues, while the shown percentage error is considered tolerable for diagnostic purposes.

Abstract: The present invention relates to a process for determining in vitro the immune status of an individual according to which: (a) a blood sample from the individual is provided, (b) at least two reagents specific to at least two products of expression of at least two target genes are provided; (c) the expression of said at least two target genes is determined, and (d) the expression of said at least two target genes respectively is compared with a reference expression, with a change in the expression of said at least two target genes relative to their reference expression indicating that the individual's immune status has changed, and a correlation between the expression of said at least two target genes with their reference expression indicating that the individual's immune status is normal; as well as a kit for determining said immune status of the individual.

Abstract: A kit for in vitro or ex vivo measurement of sCD127 expression in a biological sample, the kit including: specific tools or reagents allowing measurement of sCD127 expression in said biological sample; and a positive standard sample which is a sample calibrated to contain an amount of sCD127 which corresponds to the mean amount measured in a pool of samples from patients who are known to have developed a nosocomial infection, and/or a negative standard sample which is a sample calibrated to contain the amount of sCD127 which corresponds to the mean amount measured in a pool of samples from patients who are known not to have developed a nosocomial infection.

Abstract: A method for predicting the risk of developing a disseminated infection in a patient admitted to intensive care having no clinical symptoms of such infection includes: determining a first dose of gelsolin G1 in a biological sample from said patient originating from a first sample taken at time T1, carried out between the day of intensive care admission and 48 hours afterward; determining a second dose of gelsolin G2 in a biological sample from said patient originating from a second sample taken at time T2, carried out two to three days after the first sampling; calculating the variation between the dose of gelsolin G2 and the dose of gelsolin G1, giving a ? value; and comparing the ? value to a threshold value S determined beforehand from two patient populations admitted to intensive care, one not having developed a disseminated infection and the other having developed such an infection.

Abstract: The present invention relates to the compounds of formula (I): wherein: R2, R4 and R6, either identical or different, represent a hydrogen, chlorine bromine, iodine or fluorine atom, or a group —OH or —O-alkyl comprising from 1 to 6 carbon atoms; R2? and R4?, either identical or different, represent a hydrogen atom, or a group —OH or —O-alkyl comprising from 1 to 6 carbon atoms; with R2? and/or R4? which represent a methoxy group; n is equal to 1, 2, 3; X?CH2, O, S or N(R7); and R7 represents a hydrogen atom or an alkyl group comprising from 1 to 6 carbon atoms; as well as pharmaceutically acceptable hydrates, solvates and salts thereof.

Abstract: The invention relates to a process for determining the susceptibility to nosocomical infections in a patient, comprising the measurement of the expression of sCD127 in a biological sample.

Abstract: The subject matter of the present invention is compounds which have a 6-aminopurine backbone corresponding to formula (I): in which R1, R2, R3, X, Y and Z are as defined in any one of claims 1 to 5, and Ar is a biphenyl or a naphthyl which may be substituted with R3, for use in the treatment of cancer.

Abstract: A method for estimating the affinity ? of a first DNA strand, or “probe”, to be hybridized with a second DNA strand, or “target”, to form a hybrid of length Lbp, the method comprising: in each division of a set of M divisions of the hybrid, counting the number of times in which each hybrid of a set of P DNA strand hybrids is present in the division, the hybrids being of length k less than the length Lbp, or “k-hybrids”; for each combination of mismatches of a set of L combinations of mismatches in a hybrid of length Lbp, determining whether the pair of mismatches is present in the hybrid; and calculating the affinity ? according to the relation: ? = ? m = 1 M ? ? p = 1 P ? x m , p · ? ^ m , p + ?

Abstract: The present invention relates to the diagnosis of acquired sensory neuronopathies (SNN), and to the treatment of these disorders.

Abstract: A method for selecting in vitro compounds is capable of potentiating the effect of a DNA damage inducing chemotherapy agent for the treatment of cancer, and includes selecting compounds inhibiting the interaction between MyD88 and ERK MAP KINASE.

Abstract: A multimodal contrast and radiopharmaceutical agent for an imaging and a targeted therapy guided by imaging.

Abstract: Pharmaceutical or veterinary compositions to prevent or treat viral infections, in particular to prevent or treat influenza A, B and C virus infections.

Abstract: The present invention relates to a viral vector for expression of the cell death-inducing PUMA protein, for use in gene therapy, for example for the treatment of rheumatoid arthritis. This vector consists in particular of a recombinant adenovirus expressing the gene encoding the PUMA protein and of a recombinant baculovirus containing a coxsackie-adenovirus receptor (CAR).

Abstract: The invention provides a method of evaluating the risk of mortality in patients who present a systemic inflammatory response (SIRS) or septic syndromes, comprising measuring the expression of sCD127 in a biological sample.

Abstract: The present invention relates to a method for studying a sample containing a bacterial population of Staphylococcus aureus with a specific mass spectrometry technique allowing specific detection on the obtained mass spectrum of the presence or of the absence of a peak at an m/z value of 3005±5 Th Thomson or at 3035±5 Th Thomson, and accordingly, to the issuance of a decision conditioned by this result.

Abstract: The present invention relates to a method for improving the production of an influenza virus, and in particular influenza vaccine seeds, or a vaccine directed against an influenza virus, characterized in that the production is carried out in the presence of an inhibitor of the interaction between the Mdm2 protein and the p53 protein.

Abstract: The invention relates to a non-human primate animal model for HBV infection, said animal model being of the Cercopithecidae family.